Ignite Creation Date:
2024-05-06 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06238193
Status:
COMPLETED
Last Update Posted:
2024-02-02
First Post:
2024-01-22
Brief Title:
Molecular Characteristics of Early-onset Compared With Late-onset Colorectal Cancer
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
Molecular Characteristics of Early-onset Compared With Late-onset Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The distribution rate of microsatellite instability-high MSI-H was significantly higher in early-onset colorectal cancer and early-onset colorectal cancer has a specific mutational profile and relatively high programmed cell death ligand 1PD-L1 expression which may be used to guide personalized treatment to better control the disease
Detailed Description:
The prognosis of early-onset colorectal cancer EOCRC is worse than that of late-onset colorectal cancer LOCRC and the incidence has gradually increased in recent years so it is necessary to study the pathogenesis and explore the target of early-onset colorectal cancer patients In this study investigators aimed to explore the specific molecular pathologic map of EOCRC by comparing LOCRC This study enrolled 11344 patients with colorectal cancer treated at the Colorectal Center of the First Affiliated Hospital of Nanjing Medical University from 2003 to 2022 of whom 578 were EOCRC and 10766 were LOCRC The tumor-related mutation status and tumor mutation burden TMB of patients were detected by next-generation sequencing technology PD-L1 expression was detected by immunohistochemistry The microsatellite instability was detected by polymerase chain reaction PCR coupled with capillary electrophoresis 2B3D NCI Panel in all patients Among the 11344 patients 180 patients with EOCRC and 90 patients with LOCRC patients underwent NGS investigation Compared with LOCRC EOCRC patients generally presented a later TNM stage lower tumor differentiation and poorer histological type In LOCRC with MSI-H stupe TNM stage is earlier than whom with MSI-LMSS In addition the frequency of MSI-H was significantly higher in EOCRC 102 than LOCRC 22 The frequency of 7-mutation panel ARID1A FANCI CASP8 DGFRA DPYD TSHR and PRKCI were relatively higher in LOCRC In EOCRC group the TNM stage of MSI-H subtype patients was earlier while harbored with worse tissue differentiation and higher proportion of mucinous adenocarcinoma Besides among the EOCRC patients FBXW7 FAT1 ATM ARID1A and KMT2B mutation frequencies were significantly increased in patients with MSI-H type Comparing with MSI-H patients of LOCRC the EOCRC patients with MSI-H presented a higher mutation frequencies of FGFBR2 PBRM1 RNF43 LRP1B FBXW7 ATM and ARID1A In addition EOCRC patients were identified with higher tumor mutation burden especially in the MSI-H type PD-L1 expression calculated by tumor proportion score TPS was also elevated in EOCRC and correlated with MSI status
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None